Edesa Biotech is trading at $2.28, down 6.56%, with no company-specific cause identified in the supplied information.
- The provided sector context shows biotech strength, which does not explain Edesa Biotech’s decline.
- Search results showed no company-specific announcement dated November 3. The latest company news located was October 15 FDA clearance to expand a Phase 2 vitiligo study; it does not establish a cause for the drop.
- Intraday volume data was not available in the supplied price context.